Navigation Links
Investigational PARP inhibitor promising in BRCA-related cancers
Date:10/22/2013

BOSTON An investigational new PARP inhibitor, BMN 673, is showing early responses in patients with heavily pretreated, advanced, BRCA-related cancers of the breast and ovary, according to phase I clinical trial results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23.

When there is damage to DNA in human cells, two proteins, PARP 1 and 2, recruit proteins that can repair the damage associated with loss of BRCA proteins. Mutations in BRCA genes often result in inefficient repair of damaged DNA, which increases the risk for developing certain cancers, including cancers of the breast and ovary. Inhibiting PARP, therefore, prevents the repair of damaged DNA, leading to cell death. While some PARP inhibitors have been tested in various settings, none are approved to date.

"BMN 673 is the most potent PARP inhibitor in clinical development and has optimized pharmaceutical properties: it is well absorbed orally, has substantial single-agent antitumor activity, and has a long half-life allowing once-daily dosing," said Zev A. Wainberg, M.D., assistant professor of medicine at the Jonsson Comprehensive Cancer Center of the University of California Los Angeles School of Medicine. "The clinical data to date are promising and compare favorably with results from clinical trials with other PARP inhibitors. We observed high objective and clinical benefit response rates in BRCA-related breast and ovarian cancers at low, oral, once-daily doses.

"Based on this phase I study, we feel there's a good chance that patients with BRCA-related cancers who meet the study eligibility criteria will have disease control for a meaningful period of time with relatively few side effects. However, randomized trials are necessary to demonstrate whether this will translate into improvements in progression-free and overall survival relative to currently available therapies," said Wainberg.

He and colleagues conducted a phase I trial to evaluate the safety and efficacy of BMN 673 in a two-stage dose escalation/expansion study. So far, they have recruited 39 and 41 patients to the escalation phase and expansion phase, respectively. Patients were 18-82 years old, and they had undergone one to 13 prior therapies.

Fifty participants18 with breast cancer, 28 with ovarian cancer, three with pancreatic cancer, and one with prostate cancerhad BRCA mutations in their tumors. Wainberg reported that to date, among the patients with BRCA mutations in their tumors, 44 percent of those with ovarian cancer and 44 percent with breast cancer had an objective response. Overall, 82 percent of the ovarian cancer patients and 72 percent of the breast cancer patients had clinical benefit (measured by imaging data and/or CA 125 levels for ovarian cancers and by imaging data for breast cancers).

In patients being treated at the 1 mg dose recommended for future trials, 50 percent of the breast cancer patients with BRCA mutations had an objective response and 86 percent had clinical benefit. Of the three patients with pancreatic cancer, two have had stable disease.

Fewer than 20 percent of the patients had grade 3 adverse events including fatigue, anemia, neutropenia, and thrombocytopenia, and one patient had a grade 4 toxicity.

Given the high objective and clinical benefit response rates in breast cancer patients, the investigators have recently initiated a phase 3 trial in metastatic breast cancer with BRCA mutations, according to Wainberg.

Among those with BRCA-unrelated cancers recruited to the phase 1 trial, one of the seven currently evaluable patients with small-cell lung cancer (SCLC) has responded, according to Wainberg. This patient, whose tumor metastasized extensively, has an ongoing partial response, he explained. "A solid partial response in a patient with SCLC provides some optimism about finding indications other than BRCA-related tumors that will benefit from treatment with BMN 673," he said.


'/>"/>

Contact: Lauren Riley
lauren.riley@aacr.org
215-446-7155
American Association for Cancer Research
Source:Eurekalert

Related medicine news :

1. Targeted investigational therapy potential to overcome crizotinib resistance in lung cancers
2. Investigational malaria vaccine found safe and protective
3. Method patent issued for investigational new class of pain medication
4. Investigational agent targets gene signaling pathways to improve response for patients with CLL
5. Prostacyclin analogs and PDE 5 inhibitors synergistically stimulate ATP release from human RBCs
6. Dr. Gary McClain of JustGotDiagnosed.com Speaking at Inhibitor Family Camp
7. Possible predictive biomarker for patients who may respond to autophagy inhibitors
8. Agios research demonstrates the effects of mutant IDH1 and IDH2 inhibitors in primary tumor models
9. Cisplatin-resistant cancer cells sensitive to experimental anticancer drugs, PARP inhibitors
10. BRAF inhibitor treatment causes melanoma cells to shift how they produce energy
11. Biomarker may identify neuroblastomas with sensitivity to BET bromodomain inhibitors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/15/2019)... ... October 14, 2019 , ... An October 3 article on CNN ... The article points out that both agents are mildly abrasive; so while they may ... of modern toothpastes, they are also good at stripping the enamel off of teeth ...
(Date:10/11/2019)... ... October 11, 2019 , ... Only 6% of orthopedic surgeons in the ... well as a female physician leading the sports medicine program. These four work with ... to succeed in traditionally male-oriented fields. , Orthopedic medicine deals with the ...
(Date:10/10/2019)... ... 10, 2019 , ... Caring.com, a leading senior care referral service with Family ... for Seniors to Live. All 50 states and 302 cities in the U.S. were ... development. , According to the U.S. Census Bureau , almost 20 million ...
(Date:10/8/2019)... ... October 08, 2019 , ... ... a majority interest in Advanced Fertility Care (AFC), an advanced reproductive services (RE) ... to expand the availability of RE services to expectant families throughout Arizona and ...
(Date:10/8/2019)... (PRWEB) , ... October 08, 2019 , ... ... company, appointed distinguished innovator, Dr. Jerry Henderson as Chief Medical Officer. Dr. Henderson ... registries analytics platforms. , Dr. Henderson previously served as Chair of both ...
Breaking Medicine News(10 mins):
(Date:10/19/2019)... ... ... Beginnings Treatment Centers, a Southern California Drug and Alcohol Addiction Treatment ... and Other Drug Awareness Week at the University of California, Irvine. The objective ... other drugs through individual education and outreach programs to foster academic success and overall ...
(Date:10/17/2019)... ... 17, 2019 , ... Mount Sinai researchers have identified a ... would otherwise have no treatment options, according to a study published in October ... aggressive pediatric nervous system tumors and generally has a poor prognosis, particularly when ...
(Date:10/15/2019)... Maine (PRWEB) , ... October ... ... releases VALIDATE® LP2 linearity and calibration verification kit, for Roche cobas® analyzers, ... (Apo-A1) and Apolipoprotein B (Apo-B). Each VALIDATE® LP2 kit, liquid, ready-to-use, ...
Breaking Medicine Technology: